Gene therapy using adeno-associated virus (AAV) vectors
Neurological and metabolic diseases
Therapeutic genome editing
RNA-based approaches to treating genetic diseases
Representative Publications
Wang J, Zhang Y, Mendonca CA, Yukselen O, Muneeruddin K, Ren L, Liang J, Zhou C, Xie J, Li J, Jiang Z, Kucukural A, Shaffer SA, Gao G, Wang D. AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice. Nature. 2022. Read Publication
UMass Chan BRIDGE Fund commits $2M in six faculty projects
BRIDGE Innovation and Business Development at UMass Chan Medical School has set aside nearly $2 million in funding for six faculty-led research projects that hold promise for translation to clinical application and commercialization.
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Faculty, Research, Sharon Cantor, Paul R. Thompson, Scot A. Wolfe, Cantor Lab, Wolfe Lab, Wang Lab, Dan Wang, Molecular, Cell and Cancer Biology, Biochemistry and Molecular Biotechnology, RNA Therapeutics Institute, Marcus Ruscetti, Latest News, Li Li, BRIDGE, Top Stories,
Apr 21, 2022
UMass Chan research supports development of new suppressor-tRNA-based gene therapies
Guangping Gao, PhD, and Dan Wang, PhD, show the first evidence that a suppressor transfer RNA therapy, delivered by a recombinant adeno-associated virus, can restore protein production up to six months after treatment in a mouse model of the rare genetic disease mucopolysaccharidosis type I.
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Faculty, gene therapy, Rare Diseases, Guangping Gao, Dan Wang, RNA Therapeutics Institute, Li Weibo Institute for Rare Diseases Research, Gene Therapy Center, Microbiology and Physiological Systems, Latest News,
Nov 18, 2021
Flotte lab to develop gene therapy models for genetic lung disease
Researchers from UMass Chan Medical School have received a five-year $13.6 million program project grant from the National Heart, Lung and Blood Institute to develop new gene therapy models for alpha-1 antitrypsin deficiency, a chronic, debilitating genetic lung disease that shortens the lifespan.
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Faculty, Rare Disease, Terence Flotte, gene therapy, Guangping Gao, Wen Xue, Flotte Lab, Wang Lab, Dan Wang, Pediatrics, RNA Therapeutics Institute, Li Weibo Institute for Rare Diseases Research, Gruntman Lab, Microbiology and Physiological Systems,
Jul 29, 2021
Guangping Gao and Dan Wang partner with ASC Therapeutics to develop novel gene therapy for maple syrup urine disease
UMass Medical School researchers Guangping Gao, PhD, and Dan Wang, PhD, are working with ASC Therapeutics to bring a gene therapy for maple syrup urine disease (MSUD) to the clinic.
Read more
, Graduate School of Biomedical Sciences, Faculty, Rare Diseases, Guangping Gao, Dan Wang,
Apr 8, 2021
UMMS establishes gene therapy collaborative research agreement with Pfizer
UMass Medical School has entered into a three-year, collaborative research agreement with Pfizer to evaluate determinants that influence the manufacturing quality and yield of viral vectors used in gene therapy. The research at UMMS is being performed under the direction of Guangping Gao, PhD, and Dan Wang, PhD.
Read more
, Graduate School of Biomedical Sciences, School of Medicine, Cancer Center, Faculty, gene therapy, Guangping Gao, Dan Wang, RNA Therapeutics Institute, Li Weibo Institute for Rare Diseases Research, Gao Lab, Gene Therapy Center, Microbiology and Physiological Systems,
